Next Generation Antibody Therapeutics Market Is Set To Garner Staggering Revenues by 2020-2025 | Pfizer, Roche, Amgen, AstraZeneca, Bayer, Takeda Pharma, Biogen, Seattle Genetics

Global Next Generation Antibody Therapeutics Market Synopsis:

The report covers a forecast and an analysis of the Next Generation Antibody Therapeutics Market on a global and regional level. The study provides historical data for 2015, 2016, 2017 and 2018 along with a forecast from 2020 to 2025 based on revenue (USD Million) and volume (Kilotons). The study includes drivers and restraints of the Next Generation Antibody Therapeutics Market along with the impact they have on the demand over the forecast period.

The most important key factors driving the growth of the Global Next Generation Antibody Therapeutics Market are technological advancements, increasing prevalence of cancer, and growing collaborations among market players for the development of next-generation antibody therapeutics, improving life sciences research infrastructure, increasing applications of such therapies, and government support for related research.

Available Exclusive Sample Copy of this Report @ https://www.businessindustryreports.com/sample-request/270771 .

On the basis of regional analysis, North America is expected to dominate the Next Generation Antibody Therapeutics Market in the forecast period. This is due to high investment on R&D of the next generation antibody drugs by governments in the region. Moreover, surge in the geriatric population in the region is another factor likely to boost the market in the region. Apart from this, growing prevalence of chronic diseases in the region is expected to fuel the Next Generation Antibody Therapeutics Market in North America.

This report contains a complete product overview and its scope in the market to define the key terms and provide the clients a holistic idea of the market and its tendency. It comprehensively evaluates the Global Next Generation Antibody Therapeutics Market with different perspectives for the purpose of providing a detailed, informative, and accurate analysis of regional growth, competition, market segmentation, and other important aspects.

Global Key Players:

1 Pfizer

2 Roche

3 Bristol-Myers Squibb

4 Amgen

5 AstraZeneca

6 Bayer

7 Takeda Pharmaceuticals

8 Biogen

9 Seattle Genetics

10 ImmunoGen

11 Kyowa Hakko Kirin

12 Xencor

13 Dyax Corp and More…………….

Purchase this report online with 90 Pages, List of Tables & Figures and in-depth Table of Contents on “Global Next Generation Antibody Therapeutics Market Report 2020” @ https://www.businessindustryreports.com/buy-now/270771/single .

Product Type Segmentation

1 Antibody Drug Conjugates (ADCs)

2 Bispecific Antibodies (BsAbs)

3 Fc Engineered Antibodies

Industry Segmentation

1 Hospitals

2 Clinics

On the basis of Regional analysis, North America and Europe holds major share in global Next Generation Antibody Therapeutics market. Moreover, Asia-Pacific is expected to record higher growth rate in Next Generation Antibody Therapeutics Market during the forecast year.

Global Medical Industry News:

Bayer (June 05, 2020) - Bayer submits vericiguat for marketing authorization in the EU and Japan for the treatment of chronic heart failure - Bayer today announced the submission of two regulatory applications seeking the approval of vericiguat in the EU and Japan. Vericiguat is an investigational oral, once-daily, first-in-class soluble guanylate cyclase (sGC)-stimulator being developed to treat patients with symptomatic chronic heart failure with an ejection fraction less than 45% who have had a previous worsening heart failure event (defined as heart failure hospitalization or receiving an intravenous diuretic for heart failure without hospitalization) in combination with available heart failure therapies. Vericiguat is being jointly developed with MSD (a tradename of Merck & Co., Inc., Kenilworth, NJ, USA).

“Despite significant advances in treatment, many patients with heart failure and reduced ejection fraction still experience worsening events – even when taking guideline-based therapy. This reality puts them at an increased risk for frequent heart failure hospitalizations or the need for urgent treatment,” said Paul W. Armstrong, M.D., cardiologist and Distinguished University Professor of Medicine at the Canadian VIGOUR Centre, University of Alberta. “Vericiguat has a specific mechanism of action that distinguishes it from other current heart failure treatments. The absolute risk reduction in heart failure hospitalization and cardiovascular mortality of 4.2 per 100 patient years observed in the VICTORIA data recently presented at ACC.20/WCC Virtual and published in the New England Journal of Medicine is a gratifying result for these heart failure patients. If approved, vericiguat will give clinicians an important and welcome new option to augment existing treatment.”

“For many heart failure patients, worsening events can lead to a downward spiral where prognosis is poor and around 50% sadly die within five years of diagnosis,” said Dr. Joerg Moeller, Member of the Executive Committee of Bayer AG's Pharmaceutical Division and Head of Research and Development. “VICTORIA was the first positive contemporary outcomes trial focusing exclusively on a patient population living with symptomatic chronic heart failure with reduced ejection fraction who have had a previous worsening heart failure event. Its findings open the door for new possibilities in the management of chronic heart failure. We look forward to working with the regulatory bodies to make this treatment available in the market as soon as possible.”

Grab Your Report at an Impressive Discount @ https://www.businessindustryreports.com/check-discount/270771 .

Major Points in Table of Contents:

Global Next Generation Antibody Therapeutics Market Report 2020

1 Next Generation Antibody Therapeutics Product Definition

2 Global Next Generation Antibody Therapeutics Market Manufacturer Share and Market Overview

2.1 Global Manufacturer Next Generation Antibody Therapeutics Shipments

2.2 Global Manufacturer Next Generation Antibody Therapeutics Business Revenue

2.3 Global Next Generation Antibody Therapeutics Market Overview

2.4 COVID-19 Impact on Next Generation Antibody Therapeutics Industry

3 Manufacturer Next Generation Antibody Therapeutics Business Introduction

3.1 Pfizer Next Generation Antibody Therapeutics Business Introduction

3.2 Roche Next Generation Antibody Therapeutics Business Introduction

3.3 Bristol-Myers Squibb Next Generation Antibody Therapeutics Business Introduction

3.4 Amgen Next Generation Antibody Therapeutics Business Introduction

3.5 AstraZeneca Next Generation Antibody Therapeutics Business Introduction

3.6 Bayer Next Generation Antibody Therapeutics Business Introduction

About us

BusinessindustryReports.com is a digital database of comprehensive market reports for global industries. As a market research company, we take pride in equipping our clients with insights and data that holds the power to truly make a difference to their business. Our mission is singular and well-defined – we want to help our clients envisage their business environment so that they are able to make informed, strategic, and therefore successful decisions for themselves.

Media Contact

Business Industry Reports

Pune – India

sales@businessindustryreports.com

+19376349940

This release was published on openPR.